Navigation Links
InterMune Reports First Quarter 2009 Financial Results and Business Highlights
Date:4/30/2009

periodic reports filed with the SEC, including the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have declined significantly following the March 2007 termination of the Phase 3 INSPIRE trial of Actimmune in IPF and the risk that InterMune's revenue will continue to decline as expected; (ii) risks related to regulation by the FDA and other agencies with respect to InterMune's communications with physicians concerning Actimmune for the treatment of IPF; (iii) reimbursement risks associated with third-party payors; (iv) risks related to whether InterMune is able to obtain, maintain and enforce patents and other intellectual property; (v) risks related to significant regulatory, supply and competitive barriers to entry; (vi) risks related to the uncertain, lengthy and expensive clinical development and regulatory process, including having no unexpected safety, toxicology, clinical or other issues; (vii) risks related to achieving positive clinical trial results; (viii) risks related to timely patient enrollment and retention in clinical trials; (ix) the results of the InterMune CAPACITY trials of pirfenidone differ in some respects from those of the Shionogi & Co., Ltd. Phase 3 trial of pirfenidone and there can be no assurance that the U.S. or European regulatory authorities will approve the use of pirfenidone for the treatment of IPF; (x) the results as reported by Shionogi concerning their Phase 3 trial may differ from those published or presented in a peer-reviewed forum; and (xi) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue. The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other p
'/>"/>
SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. InterMune to Release First Quarter Financial Results on April 30
2. InterMune and Pharmasset to Discuss INFORM-1 Results From EASL Conference, April 25
3. InterMune to Present at Canaccord Adams Hepatitis C Conference
4. InterMune to Present at Citis 4th Annual Biotech Day
5. InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
6. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
7. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
8. InterMune Announces Issuance of U.S. Patent for ITMN-191
9. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
10. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
11. InterMune to Present at J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... SOUTH EASTON, Mass. , Oct. 1, 2014 /PRNewswire/ ... a worldwide leader in the development and sale of ... research market, today announced it has been invited to ... Conference in Warsaw , Poland.  The ... on October 2, 2014.  Mr. Richard T. Schumacher ...
(Date:10/1/2014)... The participants committed to not only creating unique business ... adjusting, tweaking and testing virtual models and 3D test ... , “I enjoyed being involved as a judge,” stated ... showed a commendable range exploring the technical capabilities of ... and the creativity of the contestants.” , Array Architects ...
(Date:10/1/2014)... Centreville, VA (PRWEB) October 01, 2014 ... the Diagnostic, Clinical Therapeutics, Healthcare IT, and Laboratory Testing ... and regulatory positions at the director level and above ... payers struggling to stay on top of rapid breakthroughs ... a result, many diagnostic companies have been forced to ...
(Date:9/30/2014)... available in German . ... quantum dots in a semiconductor layer. Quantum dots are small ... processes. If a short laser pulse is fired at the ... dot experiences a change in the electromagnetic field around it. ... of light by the dot. As soon as the refractive ...
Breaking Biology Technology:Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 2Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 3Pressure BioSciences, Inc. Invited to Present at the 2nd Global Life Sciences Conference in Warsaw, Poland 4Array Architects Challenges Staff to Create with 3D Printer 2Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2Ultrafast remote switching of light emission 2
... - Appointment of Company Officers ... in Authorized Shares ... ... to announce that at its Annual Shareholder Meeting held on,November 7 2007, Monica R. Brettler, Tush P. Nikollaj, Carl ...
... ... Company Raises FY2007 Targets, BEIJING, Nov. ... CMED ), a leading China-based,medical device company that ... high intensity focused ultrasound tumor,therapy system, today announced its ...
... FRANCISCO, Calif., Nov. 20 ,Exelixis, Inc. (Nasdaq: ... into an,agreement with Taconic Farms, Inc. (Hudson, NY) ... in its subsidiary Artemis Pharmaceuticals GmbH,for approximately $20 ... leader in the research, development and commercialization of,genetically ...
Cached Biology Technology:CardioMag Announces Results of 2006 Annual Shareholders Meeting and Board Meeting 2China Medical Technologies Reports Second Quarter Financial Results 2China Medical Technologies Reports Second Quarter Financial Results 3China Medical Technologies Reports Second Quarter Financial Results 4China Medical Technologies Reports Second Quarter Financial Results 5China Medical Technologies Reports Second Quarter Financial Results 6China Medical Technologies Reports Second Quarter Financial Results 7China Medical Technologies Reports Second Quarter Financial Results 8China Medical Technologies Reports Second Quarter Financial Results 9China Medical Technologies Reports Second Quarter Financial Results 10China Medical Technologies Reports Second Quarter Financial Results 11China Medical Technologies Reports Second Quarter Financial Results 12China Medical Technologies Reports Second Quarter Financial Results 13Exelixis Sells 80% Stake in Artemis to Taconic 2Exelixis Sells 80% Stake in Artemis to Taconic 3Exelixis Sells 80% Stake in Artemis to Taconic 4
(Date:10/1/2014)... Finnland, October 1, 2014 ... Bereich der Biowissenschaften   Die Biowissenschaften ... und Gehen zahlreicher Detektionstechnologien. Einige davon sind ... Standard. Die Photonen-Upconversion ist eine neuartige Detektionstechnologie, ... mit Begeisterung aufgenommen wurde. Jetzt ist diese ...
(Date:9/30/2014)... San Diego, have completed the first comprehensive numerical simulation ... the pixels in an image as data points for ... The researchers, led by J.S. Chen, the William Prager ... Engineering at UC San Diego, presented their findings on ... in Pittsburgh this month. Chen also gave a keynote ...
(Date:9/30/2014)... of Health (NIH) awarded Lawrence Livermore National Laboratory ... array system that will enable researchers to better ... and scale. , LLNL,s grant-funded project is part ... BRAIN (Brain Research through Advancing Innovative Neurotechnologies) Initiative ... understanding of the human mind and uncover ways ...
Breaking Biology News(10 mins):Innovative Verwendungslösung für die Photonen-Upconversion 2Innovative Verwendungslösung für die Photonen-Upconversion 3First comprehensive meshfree numerical simulation of skeletal muscle tissue achieved 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 2NIH taps lab to develop sophisticated electrode array system to monitor brain act 3
... Ever since human induced pluripotent stem cells were first ... equivalent to embryonic stem cells, which are sourced in early-stage ... into any cell in the body, but their origins ... not identical. Although both cell types have great potential ...
... University of Iowa researchers have found high levels of ... Indiana Harbor and Ship Canal (IHSC) in East Chicago, Ind. ... IHSC is scheduled to be dredged in spring 2012 to ... area of southern Lake Michigan. The study, published online ...
... Plutella xylostella , is one of the world,s ... many chemical and biological pesticides, and the estimated global ... In a new article published in the open ... have identified the genes expressed when the diamondback moth ...
Cached Biology News:Study reveals critical similarity between two types of do-it-all stem cells 2Study reveals critical similarity between two types of do-it-all stem cells 3Researchers find high levels of toxic PCBs in Indiana Harbor and Ship Canal 2Researchers find high levels of toxic PCBs in Indiana Harbor and Ship Canal 3Diamondback moth host-parasite interaction unraveled 2
VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
... mutS are mismatch repair minus strains of ... repair of the newly synthesized unmethylated strand ... making them helpful in such systems as ... Systems. Both ES1301 and BMH 71-18 mutS ...
Request Info...
Anti-Rat KAPPA/LAMBDA:HRP, Clone MARK-1/MARL-15, Monoclonal Antibody...
Biology Products: